AU2016257315A1 - Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status - Google Patents

Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status Download PDF

Info

Publication number
AU2016257315A1
AU2016257315A1 AU2016257315A AU2016257315A AU2016257315A1 AU 2016257315 A1 AU2016257315 A1 AU 2016257315A1 AU 2016257315 A AU2016257315 A AU 2016257315A AU 2016257315 A AU2016257315 A AU 2016257315A AU 2016257315 A1 AU2016257315 A1 AU 2016257315A1
Authority
AU
Australia
Prior art keywords
acid sequence
polypeptide
amino acid
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016257315A
Other languages
English (en)
Inventor
Clara BELZER
Patrice Daniel Cani
Willem Meindert De Vos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Wageningen Universiteit
Original Assignee
Universite Catholique de Louvain UCL
Wageningen Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL, Wageningen Universiteit filed Critical Universite Catholique de Louvain UCL
Publication of AU2016257315A1 publication Critical patent/AU2016257315A1/en
Priority to AU2020267210A priority Critical patent/AU2020267210B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016257315A 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status Abandoned AU2016257315A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020267210A AU2020267210B2 (en) 2015-05-06 2020-11-11 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166598.1 2015-05-06
EP15166598 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020267210A Division AU2020267210B2 (en) 2015-05-06 2020-11-11 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (1)

Publication Number Publication Date
AU2016257315A1 true AU2016257315A1 (en) 2017-11-23

Family

ID=74184294

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016257315A Abandoned AU2016257315A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
AU2020267210A Active AU2020267210B2 (en) 2015-05-06 2020-11-11 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020267210A Active AU2020267210B2 (en) 2015-05-06 2020-11-11 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Country Status (14)

Country Link
US (2) US10738089B2 (https=)
EP (1) EP3292135B1 (https=)
JP (1) JP6894382B2 (https=)
KR (1) KR102736980B1 (https=)
CN (1) CN107980043B (https=)
AU (2) AU2016257315A1 (https=)
DK (1) DK3292135T3 (https=)
EA (1) EA201700507A1 (https=)
ES (1) ES2934138T3 (https=)
HK (1) HK1252412A1 (https=)
IL (1) IL255405B (https=)
MX (1) MX390092B (https=)
PL (1) PL3292135T3 (https=)
WO (1) WO2016177797A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113413466A (zh) * 2020-12-15 2021-09-21 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
DK3292135T3 (da) 2015-05-06 2022-10-31 Univ Wageningen Anvendelse af et polypeptid til at fremkalde immunsignalering og/eller påvirke tarmbarrierefunktion og/eller modulere metabolsk status
KR102569754B1 (ko) * 2015-09-10 2023-08-23 위니베르시트카솔리끄드루뱅 대사장애를 치료하기 위한 살균된 아커만시아의 용도
EP3790889A4 (en) * 2017-03-07 2022-06-08 Psomagen, Inc. DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS TARGETING TOLL-LIKE RECEPTORS AND METHODS THEREOF
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
WO2020226438A1 (ko) * 2019-05-07 2020-11-12 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
WO2021060945A1 (ko) * 2019-09-25 2021-04-01 ㈜헬스바이옴 암 치료를 위한 절대혐기성 인체 장내미생물 및 이의 용도
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
EP4087859A4 (en) * 2020-01-10 2024-02-14 National Taipei University of Technology PEPTIDE INTERACTING WITH THE TOLL-LIKE RECEPTOR 2 AND COMPOSITION THEREOF
CN115666627A (zh) * 2020-03-25 2023-01-31 韩国生命工学研究院 源自嗜黏蛋白阿克曼菌的tars或其片段，及其用途
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
AU2021299904A1 (en) * 2020-07-01 2023-01-19 Compagnie Gervais Danone Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
KR102911194B1 (ko) * 2020-11-05 2026-01-13 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN115364198A (zh) * 2022-08-23 2022-11-22 广州康泽医疗科技有限公司 膜蛋白Amuc_1100在促进前脂肪细胞脂解和棕色化中的应用
CN116059254B (zh) * 2023-02-27 2025-04-18 广州知易生物科技有限公司 嗜黏蛋白阿克曼氏菌在制备用于改善和治疗多发性硬化症药物中的应用
KR102835266B1 (ko) 2023-09-11 2025-07-17 충남대학교산학협력단 아커만시아 뮤시니필라 m3-2 균주 및 이의 용도
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用
CN118063567B (zh) * 2024-03-03 2025-11-21 吉林大学 一种用于炎性肠病治疗的重组蛋白的制备与应用
CN119874827B (zh) * 2025-03-27 2025-06-13 杭州康源食品科技有限公司 一种具有免疫调节作用的九肽及其制备和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
JP3932358B2 (ja) * 2001-02-28 2007-06-20 独立行政法人産業技術総合研究所 ブラディオン遺伝子導入ショウジョウバエ株
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5290177B2 (ja) 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
EP2102350A4 (en) 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
US10576110B2 (en) 2009-05-11 2020-03-03 Societe Des Produits Nestle S.A. Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
EP2630448B1 (en) 2010-10-20 2016-12-14 Philips Lighting Holding B.V. Disaggregation apparatus
ES2565407T3 (es) 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
DK3292135T3 (da) 2015-05-06 2022-10-31 Univ Wageningen Anvendelse af et polypeptid til at fremkalde immunsignalering og/eller påvirke tarmbarrierefunktion og/eller modulere metabolsk status
KR102569754B1 (ko) 2015-09-10 2023-08-23 위니베르시트카솔리끄드루뱅 대사장애를 치료하기 위한 살균된 아커만시아의 용도
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113413466A (zh) * 2020-12-15 2021-09-21 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法

Also Published As

Publication number Publication date
PL3292135T3 (pl) 2023-01-02
JP6894382B2 (ja) 2021-06-30
US11466057B2 (en) 2022-10-11
CN107980043B (zh) 2021-09-24
NZ737765A (en) 2024-08-30
JP2018515502A (ja) 2018-06-14
AU2020267210A1 (en) 2020-12-17
IL255405A0 (en) 2017-12-31
ES2934138T3 (es) 2023-02-17
IL255405B (en) 2022-01-01
KR20180011130A (ko) 2018-01-31
EP3292135B1 (en) 2022-09-21
HK1252412A1 (zh) 2019-05-24
US20180265554A1 (en) 2018-09-20
DK3292135T3 (da) 2022-10-31
MX390092B (es) 2025-03-11
WO2016177797A1 (en) 2016-11-10
CN107980043A (zh) 2018-05-01
US10738089B2 (en) 2020-08-11
AU2020267210B2 (en) 2023-10-12
BR112017023751A2 (pt) 2018-07-31
KR102736980B1 (ko) 2024-12-02
EA201700507A1 (ru) 2018-05-31
US20210147489A1 (en) 2021-05-20
EP3292135A1 (en) 2018-03-14
CA2984985A1 (en) 2016-11-10
MX2017014111A (es) 2018-02-26

Similar Documents

Publication Publication Date Title
US11466057B2 (en) Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
JP2018515502A5 (https=)
CN109415683B (zh) 新细菌物种
Levit et al. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health
Toshimitsu et al. Effects of Lactobacillus plantarum strain OLL2712 culture conditions on the anti-inflammatory activities for murine immune cells and obese and type 2 diabetic mice
JP2013527240A (ja) バクテロイデスからの細胞成分、その組成物、およびバクテロイデスまたはその細胞成分を使用した治療方法
EP3081227A1 (en) Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics
CN117384790B (zh) 一株戊糖片球菌ks5及其在制备助睡眠药品中的应用
JP2023554676A (ja) がん治療のためのａｍｕｃ＿１１００と免疫チェックポイント調節剤との併用療法
US20230265131A1 (en) Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
Jain et al. Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures
Santos et al. Bacillus toyonensis BCT‐7112T transient supplementation improves vaccine efficacy in ewes vaccinated against Clostridium perfringens epsilon toxin
BR112021002917A2 (pt) composições compreendendo cepas bacterianas
CA2984985C (en) Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
US12447185B2 (en) GABA-producing culturable bacteria and use for improving health
JP6629955B2 (ja) 減量脂質低下のための形質転換体およびその構築方法、並びにその応用
CN102181437B (zh) 猪脂联素球状结构域蛋白gAd基因及其编码的蛋白和应用
EA040421B1 (ru) Композиция, клетки, способы получения полипептида, применение полипептида и клеток, способ лечения
BR112017023751B1 (pt) Uso de um polipeptídeo para efetuar a sinalização imune e/ou afetar a função de barreira intestinal e/ou condição metabólica modular
WO2011069860A1 (en) Novel use for the treatment of metabolic endotoxemia
TW201336989A (zh) 雙歧桿菌ｃｅｃｔ７７６５及彼於預防及／或治療過重、肥胖症及相關病徵之用途
Wu et al. Bacillus Subtilis Expressing Epidermal Growth Factors Induces Intestinal Repair and Growth-Promoting in Mice
RU2773435C2 (ru) Модифицированные грамположительные бактерии и их применение
NZ764713A (en) A bacteroides thetaiotaomicron strain and its use in reducing inflammation

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted